natgillin/translations-raw huggingface dataset:
14 prolonged-release tablets - EU/1/07/395/069 - WHITE 28 prolonged-release tablets - EU/1/07/395/026 - WHITE 30 prolonged-release tablets - EU/1/07/395/027 - WHITE 49 prolonged-release tablets - EU/1/07/395/028 - WHITE 56 prolonged-release tablets - EU/1/07/395/029 - WHITE 98 prolonged-release tablets - EU/1/07/395/030 - WHITE
14 tablet s podaljšanim sproščanjem - EU/1/07/395/069- BEL PRETISNI OMOT 28 tablet s podaljšanim sproščanjem - EU/1/07/395/026- BEL PRETISNI OMOT 30 tablet s podaljšanim sproščanjem - EU/1/07/395/027 - BEL PRETISNI OMOT 49 tablet s podaljšanim sproščanjem - EU/1/07/395/028- BEL PRETISNI OMOT 56 tablet s podaljšanim sproščanjem - EU/1/07/395/029 - BEL PRETISNI OMOT 98 tablet s podaljšanim sproščanjem - EU/1/07/395/030 - BEL PRETISNI OMOT
14 prolonged-release tablets - EU/1/07/395/070 28 prolonged-release tablets - EU/1/07/395/045 49 prolonged-release tablets - EU/1/07/395/046 56 prolonged-release tablets - EU/1/07/395/047 98 prolonged-release tablets - EU/1/07/395/048
14 tablet s podaljšanim sproščanjem EU/1/07/395/070 28 tablet s podaljšanim sproščanjem EU/1/07/395/045 49 tablet s podaljšanim sproščanjem EU/1/07/395/046 56 tablet s podaljšanim sproščanjem EU/1/07/395/047 98 tablet s podaljšanim sproščanjem EU/1/07/395/048
14 prolonged-release tablets - EU/1/07/395/072 - WHITE 28 prolonged-release tablets - EU/1/07/395/031 - WHITE 30 prolonged-release tablets - EU/1/07/395/032 - WHITE 49 prolonged-release tablets - EU/1/07/395/033 - WHITE 56 prolonged-release tablets - EU/1/07/395/034 - WHITE 98 prolonged-release tablets - EU/1/07/395/035 - WHITE
14 tablet s podaljšanim sproščanjem - EU/1/07/395/072 - BEL PRETISNI OMOT 28 tablet s podaljšanim sproščanjem - EU/1/07/395/031 - BEL PRETISNI OMOT 30 tablet s podaljšanim sproščanjem - EU/1/07/395/032 - BEL PRETISNI OMOT 49 tablet s podaljšanim sproščanjem - EU/1/07/395/033 - BEL PRETISNI OMOT 56 tablet s podaljšanim sproščanjem - EU/1/07/395/034 - BEL PRETISNI OMOT 98 tablet s podaljšanim sproščanjem - EU/1/07/395/035 – BEL PRETISNI OMOT
14 prolonged-release tablets - EU/1/07/395/073 28 prolonged-release tablets - EU/1/07/395/049 49 prolonged-release tablets - EU/1/07/395/050 56 prolonged-release tablets - EU/1/07/395/051 98 prolonged-release tablets - EU/1/07/395/052
14 tablet s podaljšanim sproščanjem EU/1/07/395/073 28 tablet s podaljšanim sproščanjem EU/1/07/395/049 49 tablet s podaljšanim sproščanjem EU/1/07/395/050 56 tablet s podaljšanim sproščanjem EU/1/07/395/051 98 tablet s podaljšanim sproščanjem EU/1/07/395/052
14 prolonged-release tablets - EU/1/07/395/076 28 prolonged-release tablets - EU/1/07/395/053 49 prolonged-release tablets - EU/1/07/395/054 56 prolonged-release tablets - EU/1/07/395/055 98 prolonged-release tablets - EU/1/07/395/056
14 tablet s podaljšanim sproščanjem EU/1/07/395/076 28 tablet s podaljšanim sproščanjem EU/1/07/395/053 49 tablet s podaljšanim sproščanjem EU/1/07/395/054 56 tablet s podaljšanim sproščanjem EU/1/07/395/055 98 tablet s podaljšanim sproščanjem EU/1/07/395/056
14 prolonged-release tablets - EU/1/07/395/077 - CLEAR 28 prolonged-release tablets - EU/1/07/395/078 - CLEAR 30 prolonged-release tablets - EU/1/07/395/079 - CLEAR 49 prolonged-release tablets - EU/1/07/395/080 - CLEAR 56 prolonged-release tablets - EU/1/07/395/081 - CLEAR 98 prolonged-release tablets - EU/1/07/395/082 – CLEAR
14 tablet s podaljšanim sproščanjem- EU/1/07/395/077 – PROZOREN PRETISNI OMOT 28 tablet s podaljšanim sproščanjem- EU/1/07/395/078 - PROZOREN PRETISNI OMOT 30 tablet s podaljšanim sproščanjem- EU/1/07/395/079 - PROZOREN PRETISNI OMOT 49 tablet s podaljšanim sproščanjem- EU/1/07/395/080 - PROZOREN PRETISNI OMOT 56 tablet s podaljšanim sproščanjem- EU/1/07/395/081 - PROZOREN PRETISNI OMOT 98 tablet s podaljšanim sproščanjem- EU/1/07/395/082 – PROZOREN PRETISNI OMOT
14 prolonged-release tablets - EU/1/07/395/083 - WHITE 28 prolonged-release tablets - EU/1/07/395/084 - WHITE 30 prolonged-release tablets - EU/1/07/395/085 - WHITE 49 prolonged-release tablets - EU/1/07/395/086 - WHITE 56 prolonged-release tablets - EU/1/07/395/087 - WHITE 98 prolonged-release tablets - EU/1/07/395/088 - WHITE
14 tablet s podaljšanim sproščanjem- EU/1/07/395/083 – BEL PRETISNI OMOT 28 tablet s podaljšanim sproščanjem- EU/1/07/395/084 - BEL PRETISNI OMOT 30 tablet s podaljšanim sproščanjem- EU/1/07/395/085 - BEL PRETISNI OMOT 49 tablet s podaljšanim sproščanjem- EU/1/07/395/086 - BEL PRETISNI OMOT 56 tablet s podaljšanim sproščanjem- EU/1/07/395/087 - BEL PRETISNI OMOT 98 tablet s podaljšanim sproščanjem- EU/1/07/395/088 - BEL PRETISNI OMOT
14 prolonged-release tablets - EU/1/07/395/089 28 prolonged-release tablets - EU/1/07/395/090 49 prolonged-release tablets - EU/1/07/395/091 56 prolonged-release tablets - EU/1/07/395/092 98 prolonged-release tablets - EU/1/07/395/093
14 tablet s podaljšanim sproščanjem - EU/1/07/395/089 28 tablet s podaljšanim sproščanjem - EU/1/07/395/090 49 tablet s podaljšanim sproščanjem - EU/1/07/395/091 56 tablet s podaljšanim sproščanjem - EU/1/07/395/092 98 tablet s podaljšanim sproščanjem - EU/1/07/395/093
14 rue Gustave Eiffel 10430 Rosières près Troyes France
14 rue Gustave Eiffel 10430 Rosières près Troyes Francija
14 tablets
(PVC/Aclar/alu)
14 tablets
(PVC/PCTFE/Alu)
14 tablets
14 ablet
14 tablets
14 filmsko obloženih tablet
14 tablets
14 tableti
14 tablets
EU/1/01/191/005
14 tablets
EU/1/10/655/006
14 tablets
promet
14 tablets
tableta
14 tablets
ŠTEVILKA SERIJE
14 tablets (PA/Alu/PVC blisters)
14 tablet (PA/Alu/PVC pretisni omoti)
14 tablets (PVC/PCTFE blisters)
14 tablet (PVC/PCTFE pretisni omoti)
14 tablets blister: Mon.
Pretisni omot s 14 tabletami: Pon.
14 tablets in 1 PVC/aluminium foil blister in wallet card with 7 x 15 mg and 7x 45 mg tablets 28 tablets in 2 PVC/aluminium foil blisters in wallet card with 7 x 15 mg and 7x 45 mg tablets 56 tablets in 4 PVC/aluminium foil blisters in wallet card with 7 x 15 mg and 7x 45 mg tablets
14 tablet v 1 pretisnem omotu PVC/aluminijasta folija v zgibanki s 7 x 15 mg in 7 x 45 mg tabletami 28 tablet v 2 pretisnih omotih PVC/aluminijasta folija v zgibanki s 7 x 15 mg in 7 x 45 mg tabletami 56 tablet v 4 pretisnih omotih PVC/aluminijasta folija v zgibanki s 7 x 15 mg in 7 x 45 mg tabletami
14 tablets in 1 PVC/aluminium foil blister in wallet card with 7 x 30 mg and 7x 60 mg tablets 28 tablets in 2 PVC/aluminium foil blisters in wallet card with 7 x 30 mg and 7x 60 mg tablets 56 tablets in 4 PVC/aluminium foil blisters in wallet card with 7 x 30 mg and 7x 60 mg tablets
14 tablet v 1 pretisnem omotu PVC/aluminijasta folija v zgibanki s 7 x 30 mg in 7 x 60 mg tabletami 28 tablet v 2 pretisnih omotih PVC/aluminijasta folija v zgibanki s 7 x 30 mg in 7 x 60 mg tabletami 56 tablet v 4 pretisnih omotih PVC/aluminijasta folija v zgibanki s 7 x 30 mg in 7 x 60 mg tabletami
14 tablets in 1 PVC/aluminium foil blister in wallet card with 7 x 30 mg and 7x 90 mg tablets 28 tablets in 2 PVC/aluminium foil blisters in wallet card with 7 x 30 mg and 7x 90 mg tablets 56 tablets in 4 PVC/aluminium foil blisters in wallet card with 7 x 30 mg and 7x 90 mg tablets
14 tablet v 1 pretisnem omotu PVC/aluminijasta folija v zgibanki s 7 x 30 mg in 7 x 90 mg tabletami 28 tablet v 2 pretisnih omotih PVC/aluminijasta folija v zgibanki s 7 x 30 mg in 7 x 90 mg tabletami 56 tablet v 4 pretisnih omotih PVC/aluminijasta folija v zgibanki s 7 x 30 mg in 7 x 90 mg tabletami
14 tablets: EU/1/08/480/001
14 tablet: EU/1/08/480/001
14 tablets: EU/1/08/480/007
14 tablet: EU/1/08/480/007
14 tablets: EU/1/08/480/013
14 tablet: EU/1/08/480/013
14 tablets: EU/1/10/632/001
14 tablet: EU/1/10/632/001
14 tablets: EU/1/10/632/008
14 tablet: EU/1/10/632/008
14 tablets: EU/1/10/632/015
14 tablet: EU/1/10/632/015
14 tablets: EU/1/11/721/001
14 tablet: EU/1/11/721/001
14 tablets: EU/1/11/721/008
14 tablet: EU/1/11/721/008
14 tablets: EU/1/11/721/015
14 tablet: EU/1/11/721/015
14 tablets: EU/1/11/723/001
14 tablet: EU/1/11/723/001
14 tablets: EU/1/11/723/008
14 tablet: EU/1/11/723/008
14 tablets: EU/1/11/723/015
14 tablet: EU/1/11/723/015
14 to less than 20†
14 do manj kot 20
14 Vials
14 Vial
14 vials + 14 pre-filled syringes (luer lock)
14 vial + 14 napolnjenih injekcijskih brizg (z luer lock nastavkom)
14 vials + 15 pre-filled syringes (luer lock)
14 vial + 15 napolnjenih injekcijskih brizg (z luer lock nastavkom)
14 x (1 vial + 1 pre-filled syringe + 1 vial adapter with needle + 2 alcohol wipes)
14 x (1 viala + 1 napolnjena injekcijska brizga + 1 adapter za vialo z iglo + 2 alkoholni blazinici)
14 x 1 (only for 1.5 mg), 28 x 1, 30 x 1, 56 x 1, 60 x 1 or 112 x 1 tablet in OPA/Alu/PVC foil film and PET/Alu peel off foil perforated unit dose blister packs are available.
Na voljo so perforirani enoodmerni pretisni omoti iz OPA/Al/PVC folije in PET/Al folije, ki se odlepi, s 14 x 1 (samo za 1,5 mg), 28 x 1, 30 x 1, 56 x 1, 60 x 1 ali 112 x 1 tableto.
14 x 1 capsules (unit
14 x 1 kapsul
14 x 1 capsules (unit
14 x 1 kapsul (posamezni odmerek)
14 x 1 capsules (unit dose)
14 x 1 kapsula (posamezni odmerek)
14 x 1 capsules (unit dose)
14 x 1 trda kapsula
14 x 1 film-coated tablet
14 x 1 filmsko obložena tableta
14 x 1 film-coated tablets
14 x 1 filmsko obložena tableta
14 x 1 hard capsules
14 x 1 trda kapsula
14 x 1 orodispersible tablet
14 x 1 orodisperzibilna tableta
14 x 1 orodispersible tablet:EU/1/09/525/026
14 x 1 orodisperzibilna tableta: EU/1/09/525/026
14 x 1 orodispersible tablets
14 x 1 orodisperzibilna tableta
14 x 1 tablet (unit
100 x 1 tableta (enkratno
14 x 1 tablet (unit
14 x 1 tableta (enkratno
14 x 1 tablet (unit
28 x 1 tableta (enkratno
14 x 1 tablet (unit
56 x 1 tableta (enkratno
14 x 1 tablet (unit dose)
14 x 1 tableta (enkratni odmerek)
14 x 1 tablet (unit dose)
14 x 1 tableta (enkratno odmerjanje)
14 x 1 tablet (unit dose)
14 x 1 tableta (za enkratni odmerek)
14 x 1 tablets
14 x 1 tablet
14 x 1 tablets
tableta
14 x 1 tablets (unit dose)
14 x 1 tableta (enkratni
14 x 1 tablets (unit dose)
14 x 1 tableta (enkratni odmerek)
14 x 1 tablets (unit dose)
14 x 1 tableta (enoodmerni
14 x 1 tablets (unit dose)
14 x 1 tableta (enoodmerni pretisni omoti)
14 x 1 tablets (unit dose)
14 x 1 tableta (za enkratni odmerek)
14 x 1, 28 x 1, 30 x 1, 56 x 1, 60 x 1 or 112 x 1 tablet in OPA/Alu/PVC foil film and PET/Alu peel off foil perforated unit dose blister packs in a box.
14 x 1, 28 x 1, 30 x 1, 56 x 1, 60 x 1 ali 112 x 1 tableta v perforiranem enoodmernem pretisnem omotu iz OPA/Al/PVC-folije in PET/Al folije, ki se odlepi, v škatli.
14 x 10 tablets
14 x 10 tablet
14 x 8.4 g syringes
14 x 8,4 g brizg
14 x1 capsules (unit dose)
14 x1 kapsula (posamezni odmerek)
14% *
np
14, 28 and 84 tablets in all-aluminium blisters
14, 28, 84 tablet v pretisnih omotih iz aluminija
14, 28, 30 and 84 tablets in all-aluminium blisters
14, 28, 30 in 84 tablet v pretisnih omotih iz aluminija
14, 28, 84 and 98 tablets in wallet packs with integrated aluminium blisters;
14, 28, 84 in 98 tablet v pretisnih zgibankah z aluminijastimi pretisnimi omoti;
14-fold less potent than gefitinib at inhibiting EGFR stimulated cell growth and has no inhibitory effect on tumour cell growth in mice.
Ta zavre prek EGRF stimulirano rast celic 14-krat manj močno kot gefitinib in pri miših ne zavira rasti tumorskih celic.
14-hydroxymetabolite:
14-hidroksimetabolit:
14-hydroxymetabolite:
klaritromicin 14
14-hydroxymetabolite: AUC: ↑ 34% (↑ 18 to ↑ 53)
AUC: ↑ 98 % (↑ 77 do ↑ 123)
14-OH-clarithromycin Cmax ↓ 97% 14-OH-clarithromycin AUC ↓ 97% 14-OH-clarithromycin Cmin ↓ 95%
Cmax 14-OH-klaritromicina ↓ 97% AUC 14-OH-klaritromicina ↓ 97% Cmin 14-OH-klaritromicina ↓ 95
14-OH-clarithromycin concentrations were not detectable when combined with PREZISTA/ritonavir.
Pri kombiniranju z zdravili PREZISTA/ritonavir koncentracije 14-hidroksi-klaritromicina niso bile zaznavne.
14-OH-clarithromycin, were increased.
14-hidroksi-klaritromicina zvišane.
14.
14 tablet
14.0 mo (11.1, 15.0)
(11,1; 15,0)
14.0 mo (11.1, 15.0)
(16,6; 21,7)
14.0 mo (11.1, 15.0)
14,0 mesecev (11,1; 15,0)
14.3 mm x 9.0 mm, green, film-coated, oval, biconvex, bevelled edge tablet debossed with M on one side of the tablet and CI90 on the other side.
Zelena, ovalna, bikonveksna filmsko obložena tableta z zglajenim robom, dimenzij 14,3 mm x 9,0 mm z vtisnjeno oznako "M" na eni strani in "CI90" na drugi strani.
14.3%
odmerek
14.3%
preiskovanca
14.4 pg/ml for 2-5 yrs and 6-11 yrs, respectively.
11 let, pa 18,9 pg/ml.
14.6 months (11.1, 17.5)
14,6 mesecev (11,1; 17,5)
14.9 (10.4, NA)
14,9 (10,4, np)
14.GENERAL CLASSIFICATION FOR SUPPLY
NAČIN IZDAJANJA ZDRAVILA
14.Remain seated or lying down for 20 minutes after injecting Ceplene.
Po injiciranju zdravila Ceplene ostanite v sedečem položaju ali se ulezite za 20 minut.
140 capsules
140 kapsul
140 film-coated tablets
140 filmsko obloženih tablet
140 film-coated tablets Titration pack
140 filmsko obloženih tablet titracijsko pakiranje
140 hard capsules
140 trdih kapsul
140 mg (1 orange 80 mg capsule and 3 grey 20 mg capsules)
140 mg (1 oranžna 80 mg kapsula in 3 sive 20 mg kapsule)
140 mg once daily  n = 304 All grades Grade 3/4
140 mg enkrat na dan  n = 304 Vse stopnje Stopnja 3/4
140 mg Q2W (N = 103)
140 mg 1-krat/2 tedna (N = 103)
140 mg Q2W (N = 153)
140 mg 1-krat/2 tedna (N = 153)
140 mg Q2W (N = 219)
140 mg 1-krat/2 tedna (N = 219)
140 tablets
140 tablet
140 tablets (titration pack)
140 tablet (titracijsko pakiranje
1400
1400 kalorij
1400 µg/kg
1400 μg/kg
1407 patients undergoing abdominal surgery treated up to 9 days
1.407 bolnikih po opravljenem kirurškem posegu v trebušni votlini, ki so se zdravili do 9 dni.
141 days
141 dni
1411 DD Naarden - NL
1411 DD Naarden - Nizozemska
1411 DD Naarden Netherlands
1411 DD Naarden Nizozemska
14129 Berlin Germany
14129 Berlin Nemčija
144 cleansing swabs
EU/1/99/127/043
144 cleansing swabs
injiciranje/infundira
144 tablets
144 tablet
144 weeks
144 tednov
145 (33.6)a
145 (33,6) a
145 mg/36.25 mg modified-release hard capsule
145 mg/36,25 mg trda kapsula s prirejenim sproščanjem
145 mg/36.25 mg modified-release hard capsules
145 mg/36,25 mg trda kapsula s prirejenim sproščanjem
146
AIS,
146 patients randomised to Simponi 50 mg, 70 were still on this treatment at week 104.
Od 146 bolnikov, ki so bili naključno razvrščeni v skupino za prejemanje zdravila Simponi v odmerku 50 mg, jih je bilo v 104. tednu 70 še vedno na tem zdravljenju.
147 mg (1.5 ml) twice daily
147 mg (1,5 ml) dvakrat na dan
147 mg (1.5 ml) twice daily
147 mg (1.5 ml) dvakrat na dan
148b
169d [105,
149 (34.5)a
149 (34,5) a
14C-azacitidine, 85 and 50 % of the administered radioactivity was recovered in urine respectively, while < 1 % was recovered in faeces.
intravenskem in subkutanem dajanju 14C-azacitidina so zaznali 85 % oziroma 50 % radioaktivnosti v urinu in le < 1 % v blatu.
14C-nelfinavir was recovered in the faeces; total faecal radioactivity consisted of nelfinavir (22 %) and numerous oxidative metabolites (78 %).
Večina (87 %) peroralnega 750 mg odmerka, ki vsebuje nelfinavir 14C, se je izločila z blatom; celotna radioaktivnost v blatu sestoji iz 22 % nelfinavirja in 78 % številnih oksidiranih presnovkov.
14C-nelfinavir was recovered in the faeces; total faecal radioactivity consisted of nelfinavir (22 %) and numerous oxidative metabolites (78 %).
Večina (87 %) peroralnega 750-mg odmerka, ki vsebuje nelfinavir 14C, se je izločila z blatom; celotna radioaktivnost v blatu sestoji iz 22 % nelfinavirja in 78 % številnih oksidiranih presnovkov.
14C-opicapone to human plasma proteins is high (99.9%) and concentration-independent.
14C-opikapona na beljakovine v človeški plazmi visoka (99,9 %) in neodvisna od koncentracije.
14x1 film-coated tablets
14x1 filmsko obložena tableta
15 - You are now ready to inject.
15 - Sedaj ste pripravljeni na injiciranje.
15 and 30 ml bottle
15 ml in 30 ml steklenička
15 applicator tips
15 aplikacijskih nastavkov
15 applicators
15 aplikatorjev
15 Changes in total fasting cholesterol levels from normal at baseline (< 4.39 mmol/l) to high (≥ 5.17 mmol/l) were observed commonly.
15Pogosto so opazovali spremembe vrednosti skupnega holesterola na tešče, ki so se z normalnih osnovnih vrednosti (< 4,39 mmol/l) zvišale na visoke (≥ 5,17 mmol/l).
15 days (Nelfinavir 750 mg q8h x 7 days)
(nelfinavir 750 mg trikrat na dan)
15 inhalers
15 inhalatorjev
15 kg to less than 20 kg
od 15 kg do manj kot 20 kg
15 l and 50 l metal cylinders with pressure control valves (body and nozzle painted in white).
15 l in 50 l kovinski cilinder s tlačnim ventilom (belo pobarvano telo in odprtina).
15 l cylinders filled at 200 bar, containing 3.2 m³ oxygen under a pressure of 1 bar at 15 ºC. 50 l cylinders filled at 200 bar, containing 10.6 m³ oxygen under a pressure of 1 bar at 15 ºC.
15 l cilinder, polnjen pri 200 barih, ki vsebujejo 3.2 m³ kisika pod pritiskom 1 bar pri 15 ºC. 50 l cilinder polnjen pri 200 barih, ki vsebujejo 10.6 m³ kisika pod pritiskom 1 bar pri 15 ºC.
15 mg every 24 hours
15 mg na 24 ur
15 mg every other day
15 mg vsak drugi dan
15 mg every other day
7,5 mg enkrat na dan2 15 mg vsak drugi dan
15 mg film-coated tablet: red, round biconvex tablets (6 mm diameter, 9 mm radius of curvature) marked with the BAYER-cross on one side and “15” and a triangle on the other side.
15 mg filmsko obložena tableta: rdeče, okrogle bikonveksne tablete (6 mm premera, 9 mm polmer ukrivljenosti), na eni strani označene z oznako BAYER in na drugi strani s številko »15« in trikotnikom.
15 mg film-coated tablets: Each film-coated tablet contains 1.42 mg lactose monohydrate.
15 mg fimsko obložene tablete: Ena filmsko obložena tableta vsebuje 1,42 mg laktoze monohidrata.
15 mg intrathecal, days 1, 8, 15, 22; Ara-C 40 mg intrathecal, days 1, 8,
MTX 15 mg intratekalno,1., 8., 15., 22. dan;
15 mg once daily
15 mg enkrat na dan
15 mg once daily on days 1-21, every 28 days
15 mg enkrat na dan od 1. do 21. dne, vsakih 28 dni
15 mg per kg bodyweight = 0.5 ml of gel per kg bodyweight Read the package insert before use.
15 mg/kg telesne mase = 0,5 ml gela/kg telesne mase Pred uporabo preberite navodilo za uporabo.
15 mg per kg bodyweight = 1 ml of gel per 5 kg bodyweight Read the package insert before use.
15 mg/kg telesne mase = 1 ml gela/5 kg telesne mase Pred uporabo preberite navodilo za uporabo.
15 mg tablet: blue, triangular (major axis: 6.58 mm, minor axis: 6.20 mm), shallow-convex, debossed with “OTSUKA” and “15” on one side.
45-mg tableta: modra, kvadratna (6,8 mm na stran, večja os: 8,2 mm), plitko konveksna z vtisnjenim napisom "OTSUKA" in "45" na eni strani.
15 mg tablets: Opadry Blue containing hypromellose (E464), titanium dioxide (E171), polyethylene glycol 6000, indigo carmine aluminium lake (E132), brilliant blue FCF aluminium lake (E133) and iron oxide black (E172)
15 mg tablete: Opadry modri, ki vsebuje hipromelozo (E464), titanov dioksid (E171), laktozo monohidrat, makrogol 6000, barvilo indigotin (E132), barvilo modro FCF (E133) in črni železov oksid (E172)
15 mg/day doses of vortioxetine.
15 mg/dan vortioksetina.
15 mg/kg q 3 weeks
15 mg/kg na 3 tedne
15 mg/kg/day as 2 divided doses (n = 17)
15 mg/kg na dan v obliki 2 deljenih odmerkov
15 mg/kg/day as 2 divided doses (n = 17)
15 mg/kg na dan v obliki 2 deljenih odmerkov (n = 17)
15 mg/ml amprenavir
15 mg/ml amprenavirja
15 mg: Round and yellow, marked with "A" over "641" on one side and "15" on the other.
Okrogle oblike in rumene barve, označene z "A" nad "641" na eni strani in 15 na drugi.
15 micrograms HA** Per 0.1 ml dose
15 mikrogramov HA** na 0,1 ml odmerka
15 min) infusion time should only be used for patients with normal renal function or mild renal impairment.
15 min) se uporablja samo pri bolnikih z normalno ledvično funkcijo ali blago ledvično okvaro.
15 ml (three 5 ml vials)
15 ml (tri 5 ml viale)
15 ml bottle and a 3ml oral dosing syringe
15 ml plastenka in 3 ml odmerna brizga
15 ml clear glass Type I vial with a bromobutyl rubber stopper and a flip-off cap.
15 ml viala tipa I iz prozornega stekla z zaporko iz brombutilne gume in pokrovčkom Flip Off.
15 ml clear glass Type I vial with a bromobutyl rubber stopper and aluminium seal and a plastic flip- off cap containing 10 ml of concentrate for solution for infusion.
15 ml viala iz prozornega stekla tipa I z bromobutilno gumijasto zaporko in aluminijastim pečatom ter plastično dvižno zaporko z 10 ml koncentrata za raztopino za infundiranje.
15 ml colourless glass vial with a bromobutyl rubber stopper and an aluminium crimp cap with plastic flip-off component.
15-mililitrska brezbarvna steklena viala, z brombutilnim gumijastim zamaškom in aluminijasto zaporko s plastičnim zaščitnim pokrovčkom.
15 ml colourless type 1 glass vial with grey bromobutyl rubber stopper and sealed with a blood red colour flip-off aluminium seal
15-mililitrska viala iz prozornega stekla tipa 1 s sivim brombutilnim zamaškom in živordečo aluminijasto zaporko.
15 ml in an amber glass bottle with dropper applicator (LD-polyethylene), and child-resistant screw cap (polypropylene).
15 ml v steklenici iz jantarjevega stekla z zaporko s kapalko (iz polietilena nizke gostote) in z za otroke varno navojno zaporko (iz polipropilena).
15 ml or 30 ml bottle.
Plastenke po 15 ml ali 30 ml.
15 orodispersible tablets
15 orodisperzibilnih tablet
15 OTHER INFORMATION
DRUGE INFORMACIJE
15 patients were between the age of 6 to less than 18 years old and 6 patients were less than 6 years old (total of 393 exposures of NovoThirteen in paediatric subjects (less than 18 years old).
15 bolnikov je bilo starih več kot 6 in manj kot 18 let ter 6 bolnikov je bilo starih manj kot 6 let (skupaj 393 izpostavljenosti zdravilu NovoThirteen pri pediatričnih bolnikih, mlajših od 18 let).
15 pipettes
15 merilnih kapalk
15 pipettes
15 pipet
15 rue des Pyrénées 91090 Lisses France
15 rue des Pyrénées 91090 Lisses Francija
15 tablets
15 tablete
15 to 71 M
15 do 71 m
15 vials + 15 pre-filled syringes (luer lock)
15 vial + 5 napolnjenih injekcijskih brizg (z luer lock nastavkom)
15 vials with powder and 15 pre-filled syringes with solvent.
15 vial s praškom in 15 napolnjenih injekcijskih brizg z vehiklom.
15 vials with powder and 15 pre-filled syringes with solvent:
15 vial s praškom in 15 napolnjenih injekcijskih brizg z vehiklom:
15 yrs
15 let
15 µg haemagglutinin per strain per 0.1 ml dose
15 mikrogramov hemaglutinina na sev na 0,1 ml na odmerek
15 µg haemagglutinin per strain per 0.1 ml dose
15 mikrogramov hemaglutinina na sev na 0,1 ml odmerek
15 – 20 psi (1.0 – 1.4 bar)
15–20 psi (1,0–1,4 bara)
15% (8%)
Bolezni sečil
15, 22; methylprednisolone 40 mg intrathecal, days 1, 8, 15, 22
Ara-C 40 mg intratekalno, 1., 8., 15., 22. dan; metilprednizolon 40 mg intratekalno, 1., 8., 15., 22. dan
15, 42, 100 or 200 ml bottle with two measuring syringes.
Plastenke po 15, 42, 100 ali 200 ml z dvema merilnima brizg.
15, boulevard Charles de Gaulle - 92707 Colombes Cedex, France
15, boulevard Charles de Gaulle - 92707 Colombes Cedex, Francija
15, boulevard Charles de Gaulle 92707 Colombes Cedex
15, boulevard Charles de Gaulle 92707 Colombes Cedex Francija
15.
Pogosti
15.0 mo (14.1, 17.9)
(14,1; 17,9)
15.0 mo (14.1, 17.9)
15,0 mesecev (14,1; 17,9)
15.2 months, NR).
15,2 meseca, NR).
15.4 wks (8.4, 16.9)
15,4 tedna (8,4, 16,9)
15.5
(n=110)
15.5 months for the pemetrexed arm and 10.3 months for the placebo arm, hazard ratio = 0.70 (95 % CI = 0.56 - 0.88, p = 0.002).
10,3 mesecev za skupino s placebom (razmerje tveganja = 0,70, 95% CI: 0,56 - 0,88, p = 0,002).
15.5% had received prior radiotherapy and 28.4% prior chemotherapy.
15,5 % jih je predhodno prejemalo radioterapijo, 28,4 % pa kemoterapijo.
15.6
ARROW
15.Dispose of the syringe in the puncture-proof container as instructed.
Brizgo odvrzite v poseben zabojnik v skladu z navodili.
15.INSTRUCTIONS ON USE
NAVODILA ZA UPORABO
150 (15x10x1) capsules
150 (15x10x1) kapsul
150 (25x6x1) capsules
150 (25x6x1) kapsul
150 (U/ml)
150 (e./ml)
150 children were followed-up for three years without booster, additional 150 children received a booster after 1 year (0.25 ml if aged <3 years at time of the booster, 0.5 ml if aged 3 years and above) and were followed-up for further two years.
150 otrok so spremljali 3 leta brez obnovitvenega odmerka, drugih 150 otrok je po enem letu prejelo obnovitveni odmerek (0,25 ml, če so bili v času prejema obnovitvenega odmerka stari manj kot 3 leta; 0,5 ml, če so bili stari 3 leta ali več) ter so jih spremljali še dve leti.